Skip to main content
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. — Investor Relations & Filings

Ticker · XBIO ISIN · US9840155033 LEI · 5493002WV0KYX8JXAH52 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2025-10-14 Capital/Financing Update
Country US United States of America
Listing US XBIO

About Xenetic Biosciences, Inc.

https://www.xeneticbio.com/

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing proprietary technology platforms for immune-oncology. The company's development pipeline is centered on its XCART platform, a personalized CAR T-cell therapy technology, and its DNase-based oncology platform. The DNase platform is designed to improve cancer therapies by targeting Neutrophil Extracellular Traps (NETs), which are implicated in cancer progression, metastasis, and resistance to treatments. Xenetic's research aims to address multiple high-value, difficult-to-treat cancer indications, including pancreatic cancer and other solid tumors.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an underwritten public offering of common stock, including details about the underwriting agreement, offering price, and use of proceeds. It also includes references to exhibits such as the underwriting agreement and legal opinion. There are no financial statements or detailed financial analysis present, and the document is not an annual or quarterly report. The primary focus is on a financing event (public offering of shares). Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report or a certification. Hence, the classification is CAP with high confidence.
2025-10-14 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by Xenetic Biosciences, Inc. It details the terms of the offering, underwriting arrangements, use of proceeds, and risk factors. This type of filing is a capital raising document used to inform investors about a securities offering. It is not an annual or quarterly report, earnings release, management discussion, or any other type of financial or governance report. It clearly fits the definition of a Capital/Financing Update (CAP) as it provides updates on the company's fundraising and capital structure changes through the offering of new shares.
2025-10-11 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 preliminary prospectus supplement filed pursuant to Rule 424(b)(5) with the SEC. It details an offering of common stock by Xenetic Biosciences, Inc., including offering price, underwriting discounts, use of proceeds, and risk factors. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not an annual or quarterly report, audit report, earnings release, or any other type of financial or governance report. The document clearly relates to a capital/financing update regarding a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2025-10-10 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 13, 2025, by Xenetic Biosciences, Inc. It reports the results of operations and financial condition for the three months ended June 30, 2025. The document includes a press release as Exhibit 99.1 announcing quarterly financial results. The Form 8-K is a current report used to announce material events, including earnings releases. The text explicitly states it is announcing results for the quarter, which aligns with an Earnings Release. The document is about 6,324 characters, which is typical for an 8-K earnings release filing. It is not a full quarterly report (10-Q) or annual report (10-K), but a current report announcing earnings results. Therefore, the appropriate classification is Earnings Release (ER).
2025-08-13 English
FORM 10-Q FOR JUN 2025
Interim / Quarterly Report Q2 2025
2025-08-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 14, 2025, by Xenetic Biosciences, Inc. It announces the results of operations and financial condition for the three months ended March 31, 2025. The document includes a press release as an exhibit, which is typical for an earnings release announcement. The text explicitly states that the press release announces results for the quarter, which aligns with the definition of an Earnings Release (ER). The document is not the full quarterly report or financial statements but a current report announcing quarterly financial results. Therefore, the appropriate classification is Earnings Release (ER).
2025-05-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.